Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY). / Lindblad, U.; Lindberg, Gunnar; Månsson, Nils-Ove; Ranstam, Jonas; Tyrberg, Maria; Jansson, S.; Lindwall, K.; Svärdh, Mona; Kindmalm, L.; Melander, Arne.

I: Diabetes, Obesity and Metabolism, Vol. 13, Nr. 2, 2011, s. 185-188.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Lindblad, U. ; Lindberg, Gunnar ; Månsson, Nils-Ove ; Ranstam, Jonas ; Tyrberg, Maria ; Jansson, S. ; Lindwall, K. ; Svärdh, Mona ; Kindmalm, L. ; Melander, Arne. / Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY). I: Diabetes, Obesity and Metabolism. 2011 ; Vol. 13, Nr. 2. s. 185-188.

RIS

TY - JOUR

T1 - Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

AU - Lindblad, U.

AU - Lindberg, Gunnar

AU - Månsson, Nils-Ove

AU - Ranstam, Jonas

AU - Tyrberg, Maria

AU - Jansson, S.

AU - Lindwall, K.

AU - Svärdh, Mona

AU - Kindmalm, L.

AU - Melander, Arne

PY - 2011

Y1 - 2011

N2 - The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.

AB - The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.

KW - IFG

KW - prevention

KW - primary care

KW - randomized trial

KW - sulphonylurea

KW - type 2

KW - diabetes

U2 - 10.1111/j.1463-1326.2010.01331.x

DO - 10.1111/j.1463-1326.2010.01331.x

M3 - Article

VL - 13

SP - 185

EP - 188

JO - Diabetes, Obesity and Metabolism

T2 - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -